A Personalized Approach to Disease Management in Psoriasis

Bhavesh Shah, PharmD, and Robert Groves, MD, discuss the priorities payers should be taking into account when managing psoriasis treatment.

The panel details the clinical and economic burden when patients switch between agents in plaque psoriasis.

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.

Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.

Ryan Haumschild, PharmD, MS, MBA discusses the potential to lower total costs through care pathways designed to start patients with plaque psoriasis and metabolic syndrome on treatments that have shown to have better overall outcomes, such as tildrakizumab.

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.

Bhavesh Shah, PharmD, elaborates on switching biologics in psoriasis treatment.

Dr Lebwohl explains how he can recognize who will respond early to psoriasis treatments and who won’t respond at all.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Drs Lebwohl and Groves list support services to help with patient adherence.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.